

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/667,676
				Filing Date	2003-09-22
				First Named Inventor	G. Boehm
				Art Unit	1615
				Examiner Name	Carlos A. Azpuru
Sheet	1	of	3	Attorney Docket No: 224562	

US PATENT DOCUMENTS					
Exami ner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/C.A./ ↓	A1	3,845,770	1974-11-05	Theeuwes, et al.	Entire document
	A2	3,879,555	1975-04-22	Pachter, et al.	Entire document
	A3	4,088,864	1978-05-09	Theeuwes, et al.	Entire document
	A4	4,606,909	1986-08-19	Bechgaard, et al.	Entire document
	A5	4,795,327	1989-01-03	Gaylord, et al.	Entire document
	A6	4,834,965	1991-08-28	Martani, et al.	Entire document
	A7	4,844,907	1989-07-04	Elger, et al.	Entire document
	A8	4,867,987	1989-09-19	Seih, P.	Entire document
	A9	4,871,546	1989-10-03	Feltz, et al.	Entire document
	A10	5,149,538	1992-09-22	Granger, et al.	Entire document
	A11	5,236,714	1993-08-17	Lee, et al.	Entire document
	A12	5,266,331	1993-11-30	Oshlack, et al.	Entire document
	A13	5,376,384	1994-12-27	Eichel, et al.	Entire document
	A14	5,478,573	1995-12-16	Eichel, et al.	Entire document
	A15	5,451,408	1995-09-15	Mezei, et al.	Entire document
	A16	5,478,573	1995-12-26	Eichel, et al.	Entire document
	A17	5,508,042	1996-04-16	Oshlack, et al.	Entire document
	A18	5,549,912	1996-08-27	Oshlack, et al.	Entire document
	A19	5,529,790	1996-06-25	Eichel, et al.	Entire document
	A20	5,614,218	1997-03-25	Olsson, et al.	Entire document
	A21	5,629,011	1997-05-13	Illum, L.	Entire document
	A22	5,656,295	1997-08-12	Oshlack, et al.	Entire document
	A23	5,672,360	1997-09-30	Sackler, et al.	Entire document
	A24	5,725,883	1998-03-10	Staniforth, et al.	Entire document
	A25	5,834,024	1998-11-10	Heinicke, et al.	Entire document
	A26	5,866,164	1999-02-02	Kuczynski, et al.	Entire document
	A27	5,935,975	1999-08-10	Rose, et al.	Entire document
	A28	5,968,551	1999-10-19	Oshlack, et al.	Entire document
	A29	6,033,687	2000-03-07	Heinicke, et al.	Entire document
	A30	6,103,261	2000-08-15	Chasin, et al.	Entire document
	A31	6,214,385	2001-04-10	Heinicke, et al.	Entire document
	A32	6,316,031	2001-11-13	Oshlack, et al.	Entire document
	A33	6,375,957	2002-04-23	Kaiko, et al.	Entire document
	A34	6,495,120	2002-12-17	McCoy, et al.	Entire document

EXAMINER

/Carlos Azpuru/

DATE CONSIDERED

09/23/2009

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional) * Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/667,676
				Filing Date	2003-09-22
				First Named Inventor	G. Boehm
				Art Unit	1615
				Examiner Name	Carlos A. Azpuru
Sheet	2	of	3	Attorney Docket No: 224562	

US PATENT DOCUMENTS					
Exami ner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/C.A./	A35	6,635,277	2003-10-21	Sharma, et al.	Entire document
↓	A36	6,872,407	2005-03-29	Notario, et al.	Entire document
↓	A37	7,056,532	2006-06-06	Kabanov, et al.	Entire document
↓	A38	7,081,255	2006-07-25	Bact, et al.	Entire document
↓	A39	7,101,574	2006-09-05	Criere, et al.	Entire document
↓	A40	7,125,561	2006-10-24	Sackler, et al.	Entire document
↓	A41	2003-0026838A1	2003-02-06	Farrell, J.	Entire document
↓	A42	2003-0044458A1	2003-03-06	Wright, et al.	Entire document
↓	A43	2003-0049317A1	2003-03-13	Lindsay, D.	Entire document
↓	A44	2003-0068375A1	2003-04-10	Wright, et al.	Entire document
↓	A45	2003-0124185A1	2003-07-03	Oshlack, et al.	Entire document
↓	A46	2003-0228357A1	2003-12-11	Johnson, et al.	Entire document
/C.A./	A47	2005-0169990A1	2005-08-04	Kao, et al.	Entire document

FOREIGN PATENT DOCUMENTS						
Exami ner Initials *	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
/C.A./	B1	EP 502642A1	1992-09-09	Reckitt and Coleman Prod.	Entire document	
↓	B2	CA 2229621	1998-03-11	BASF Aktiengesellschaft	Entire document	
↓	B3	JP59122425A2	1984-07-14	Kaken Pharmaceut Co. Ltd.	English abstract	
/C.A./	B4	JP10130142A2	1998-05-19	Zensei Yakuhim Kogyo KK	English abstract	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/C.A./	C1	Bodmeier, R.; Guo, X. Sarabia, P.F.; Skultery, P.F.; "The influence of buffer species and strength on diltiazem HCl release from beads coated with aqueous cationic dispersions"; Pharm. Res. Vol. 13, pp. 52-56 (1996)	

EXAMINER

/Carlos Azpuru/

DATE CONSIDERED

09/23/2009

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional) ‡ Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/667,676
				Filing Date	2003-09-22
				First Named Inventor	G. Boehm
				Art Unit	1615
				Examiner Name	Carlos A. Azpuru
Sheet	3	of	3	Attorney Docket No: 224562	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/C.A./ ↓	C2	Donbrow, et al. Gradation of microcapsule wall porosity by deposition of polymer mixtures (Eudragit RL and Eudragit RS). Phase Separation of Polymer Mixtures and Effects of External Media and Conditions on Release. J. Microencapsulation, Vol. 12, No. 3, pp. 273-285 (1995)		
	C3	Felton, et al. Influence of Insoluble Excipients on Film Coating Systems. Drug Dev. Ind. Pharmacy; Vol. 28, No. 3, pp. 225-243 (2002)		
	C4	Mendelson et al. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin. Pharm. Ther. 60:105-114 (1996)		
	C5	Rao, et al. Effect of Sodium Lauryl Sulfate on the Release of Rifampicin from Guar Gum Matrix. Indian Journal of Pharmaceutical Science. pp. 404-406 (2000) (Abstract)		
	C6	Wagner, et al. Influence of chloride ion exchange on the permeability and drug release of Eudragit RS 30 D films. J. Cont. Rel. Vol. 82, pp. 385-397 (2002)		
	C7	Weinberg et al. Sublingual absorption of selected opioid analgesics. Clin. Pharmacol. Ther. 44:335-340 (1988)		
	C8	Weinhold et al. Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug and Alcohol Dependence, 30: 263-274 (1992)		
	C9	Wells, et al. Effect of Anionic Surfactants on the Release of Chlorpheniramine Maleate From an Inert, Heterogeneous Matrix. Drug Development and Industrial Pharmacy, 18(2): 175-186 (1992)		

EXAMINER

/Carlos Azpuru/

DATE CONSIDERED

09/23/2009

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance with MPEP 609. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached